Merck Discontinued Antibiotic Recarbrio in U.S. Market
Hospitals and providers must identify alternative treatment protocols for pneumonia and complicated infections.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to prioritize public health needs over their own market potential?
Merck has ceased the supply of the three-drug injection Recarbrio in the United States. The decision comes seven years after the FDA first approved the antibiotic for treating complicated infections.
Why it matters
The discontinuation removes an established treatment option for ventilator-associated pneumonia and complicated stomach or urinary tract infections from the hospital supply chain. Providers must now pivot to secondary therapies to maintain standards of care for these critical conditions.
The withdrawal affects a three-drug combination injection that reached the U.S. market seven years ago. Sales figures for the product were not publicly disclosed in the company's regulatory filings.
The players
Merck
A global pharmaceutical company that develops and manufactures prescription medicines, vaccines, and animal health products.
FDA
The federal agency responsible for protecting public health by regulating the safety and efficacy of medical products in the United States.
The details
Merck discontinued the product by ceasing all supply chain distribution to the domestic U.S. market. The injection was specifically formulated to treat patients suffering from hospital-acquired pneumonia, ventilator-associated pneumonia, and complex intra-abdominal or urinary tract infections. Clinical departments must now update their formularies and treatment protocols to replace the drug with suitable alternatives.
Timeline
2019: Recarbrio received FDA approval.
September 2026: Merck discontinued Recarbrio in the U.S.
Market Landscape
This withdrawal disrupts the standard drug development cycle where therapies remain available for decades post-approval. It highlights the volatility in hospital-focused pharmaceutical portfolios, where companies frequently rebalance inventories based on shifting clinical demand.
Facility managers and clinical procurement teams should immediately verify current inventory levels and coordinate with pharmacy leads to secure alternatives. Ensure that clinical guidelines for ventilator-associated pneumonia are updated to account for the removed therapy.
The takeaway
The removal of a specialized antibiotic requires immediate shifts in hospital clinical procurement to avoid treatment gaps. Monitor departmental drug formularies to ensure compliant alternatives are locked in for the upcoming quarter.
Further reading
For more on evolving standards of care, see the Healthcare section.
Source note: This article includes information reported by STAT.
Live Poll
Do you trust pharmaceutical companies to prioritize public health needs over their own market potential?
